|
|
|
| Analysis of adverse reactions in patients treated with injections of the anti-tumor drug Paclitaxel |
| SHENG Nan |
| Department of Pharmacy,Central Hospital of Wafangdian City |
|
|
|
|
Abstract Objective To observe the incidence of adverse reactions in patients treated with injections of anti-tumor drug Paclitaxel in Central Hospital of Wafangdian City,Liaoning Province from December 2017 to December 2019.Methods The clinical data of 130 patients treated with injections of Paclitaxel from December 2017 to December 2019 in the Central Hospital of Wafangdian City,Liaoning Province were retrospectively analyzed,and the incidence of adverse reactions in the patients were observed and analyzed.Results All the 130 patients had adverse reactions of varying degrees,among which the incidence rates of bone marrow suppression (23.08%),alopecia (19.23%) and intestinal reactions (16.92%) were high,and the incidence rates of other adverse reactions such as allergic reactions,joint or muscle pain,blood system diseases,nephrotoxicity,cardiotoxicity and fever were low.In patients of all ages,the incidence of adverse reactions was higher in patients ＞60 years old,accounting for 50.00%.More patients (43.85%) experienced adverse reactions after 8 to 15 days of Paclitaxel treatment.Conclusion Patients treated with the Paclitaxel Injection,the anti-tumor drug,will have adverse reactions of varying degrees,and the high-risk period of adverse reactions is 8 to 15 days after the beginning of the use of Paclitaxel.In the monitoring of drug safety in patients of all ages,special attention should be paid to the specific situation of elderly patients after medication.Prophylactic medication is recommended to reduce the incidence of adverse drug reactions.
|
|
|
|
|
|
| [1] |
田舒桐，张雪玉.两种铂类联合紫杉醇在卵巢癌化疗中不良反应及临床近期疗效的对比[C].//2019 中国肿瘤学大会论文集，2019：6283.
|
| [2] |
周艳.抗肿瘤药紫杉醇的不良反应及临床合理用药分析[J].中国现代药物应用，2017，11（9）：138-139.
|
| [3] |
邢雪梅.抗肿瘤药物不良反应的临床观察研究[J].世界临床医学，2019，13（4）：134-135.
|
| [4] |
乐可佳，施芳红.抗肿瘤药物不良反应59 例[J].医药导报，2017，36（Z1）：139-141.
|
| [5] |
韦灵玉，邱晓春，周彦来，等.我院907 例抗肿瘤药物不良反应分析[J].中国药物警戒，2017，14（4）：242-245.
|
| [6] |
吴海伟，白羽，刘红，等.我院273 例抗肿瘤药物不良反应报告分析[J].中国医药导报，2017，14（14）：126-130.
|
| [7] |
李丹.168 条静脉用药集中调配中心审核的抗肿瘤药静脉用药不合理医嘱分析[J].中国医院用药评价与分析，2018，18（10）：1407-1408，1411.
|
| [8] |
林美凤，吴丽贤.抗肿瘤药物的不良反应分析[J].中外医疗，2018，37（13）：114-115，118.
|
| [9] |
何小霞，王俊，谭斌，等.基于紫杉醇不良反应的合理用药分析[J].中国药业，2019，28（17）：94-96.
|
| [10] |
邓引，杨健.某院紫杉醇注射剂用药情况与不良反应相关因素分析[J].药物流行病学杂志，2019，28（5）：302-307.
|
| [11] |
金经，王先利，孙慧，等.某院妇科病房紫杉醇引起严重药物不良反应的危险因素分析及持续质量改进[J].中国医院药学杂志，2018，38（21）：2245-2248.
|
| [12] |
赵丽杰，吴红杰.抗肿瘤药紫杉醇的不良反应及临床合理用药分析[J].中国医药指南，2018，16（9）：140-141.
|
| [13] |
田舒桐，张雪玉，刘瑞，等.两种铂类联合紫杉醇在卵巢癌化疗中不良反应的对比[J].宁夏医学杂志，2018，40（8）：741-744.
|
| [14] |
吴海肖，李淑玲.紫杉醇血药浓度与不良反应的相关性研究[J].临床合理用药杂志，2019，12（17）：71-72.
|
| [15] |
张鹤.抗肿瘤药物紫杉醇的不良反应的临床分析[J].中国药物滥用防治杂志，2019，25（3）：153-155.
|
|
|
|
